西妥昔-话题@MedSci

#西妥昔#

72篇内容 | 1882人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1679453, encodeId=75c616e945353, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益, objectType=article, longId=154857, objectId=098c15485ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=098c15485ec3, replyNumber=0, likeNumber=82, createdTime=2019-07-28, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=098c15485ec3, moduleTitle=西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=098c15485ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679455, encodeId=435616e9455b3, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌, objectType=article, longId=159008, objectId=21e215900857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e215900857, replyNumber=0, likeNumber=64, createdTime=2019-09-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e215900857, moduleTitle=CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e215900857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679459, encodeId=bfea16e9459e7, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, objectType=article, longId=181909, objectId=dfaf18190961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfaf18190961, replyNumber=0, likeNumber=108, createdTime=2020-05-27, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfaf18190961, moduleTitle=NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfaf18190961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679458, encodeId=84fa16e945867, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=90, createdTime=2020-07-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679447, encodeId=8a1216e9447e8, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=J Clin Oncol：RAS野生型转移性结直肠癌：西妥昔单抗联合FOLFOX-4 vs FOLFOX-4, objectType=article, longId=149868, objectId=57f314986823, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f314986823, replyNumber=0, likeNumber=56, createdTime=2018-11-26, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f314986823, moduleTitle=J Clin Oncol：RAS野生型转移性结直肠癌：西妥昔单抗联合FOLFOX-4 vs FOLFOX-4, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57f314986823)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679456, encodeId=007d16e94564b, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA ONCOL：转移性结直肠癌首次进展后：贝伐单抗vs西妥昔单抗+化疗, objectType=article, longId=161420, objectId=f2d1161420f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2d1161420f3, replyNumber=0, likeNumber=52, createdTime=2019-05-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2d1161420f3, moduleTitle=JAMA ONCOL：转移性结直肠癌首次进展后：贝伐单抗vs西妥昔单抗+化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2d1161420f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679449, encodeId=15e016e94494f, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：奥拉帕尼联合西妥昔单抗及放疗治疗局部晚期头颈部肿瘤, objectType=article, longId=152302, objectId=ed0e152302b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed0e152302b7, replyNumber=0, likeNumber=59, createdTime=2019-08-12, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed0e152302b7, moduleTitle=CLIN CANCER RES：奥拉帕尼联合西妥昔单抗及放疗治疗局部晚期头颈部肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed0e152302b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679454, encodeId=c1a316e94549b, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：miR-31-3p表达可以预测西妥昔单抗疗效, objectType=article, longId=158586, objectId=7cca15858623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cca15858623, replyNumber=0, likeNumber=63, createdTime=2019-11-27, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cca15858623, moduleTitle=CLIN CANCER RES：miR-31-3p表达可以预测西妥昔单抗疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cca15858623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679448, encodeId=bbac16e94487c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：抑制EphB4-ephrin-B信号可以增强头颈部肿瘤对西妥昔单抗-放疗的治疗反应, objectType=article, longId=150046, objectId=a12715004629, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a12715004629, replyNumber=0, likeNumber=74, createdTime=2019-01-24, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a12715004629, moduleTitle=CLIN CANCER RES：抑制EphB4-ephrin-B信号可以增强头颈部肿瘤对西妥昔单抗-放疗的治疗反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a12715004629)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679451, encodeId=df4816e94513c, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet：西妥昔单抗vs顺铂治疗HPV阳性口咽鳞状细胞癌, objectType=article, longId=153668, objectId=0cec153668c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cec153668c0, replyNumber=0, likeNumber=62, createdTime=2019-01-24, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cec153668c0, moduleTitle=Lancet：西妥昔单抗vs顺铂治疗HPV阳性口咽鳞状细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cec153668c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679452, encodeId=7db116e9452d9, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=郭晔教授：CHANGE-2研究显示——西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益, objectType=article, longId=154502, objectId=585815450285, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=585815450285, replyNumber=0, likeNumber=61, createdTime=2019-02-17, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=585815450285, moduleTitle=郭晔教授：CHANGE-2研究显示——西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=585815450285)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679445, encodeId=bcae16e944575, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, objectType=article, longId=136508, objectId=62cf1365087c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cf1365087c, replyNumber=0, likeNumber=58, createdTime=2018-10-24, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cf1365087c, moduleTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62cf1365087c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679450, encodeId=2fa416e9450d6, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Lancet：西妥昔单抗vs顺铂用于HPV阳性口腔癌, objectType=article, longId=153667, objectId=f0c515366e77, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0c515366e77, replyNumber=0, likeNumber=61, createdTime=2019-05-11, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0c515366e77, moduleTitle=Lancet：西妥昔单抗vs顺铂用于HPV阳性口腔癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0c515366e77)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679446, encodeId=731f16e9446ff, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Ann Oncol：可切除的食管癌：放化疗和手术联合或不联合西妥昔单抗有差吗？, objectType=article, longId=144328, objectId=40e314432837, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40e314432837, replyNumber=0, likeNumber=63, createdTime=2018-08-16, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40e314432837, moduleTitle=Ann Oncol：可切除的食管癌：放化疗和手术联合或不联合西妥昔单抗有差吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40e314432837)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679443, encodeId=2eb316e94434b, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行, objectType=article, longId=127050, objectId=34ed12e050b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ed12e050b3, replyNumber=0, likeNumber=52, createdTime=2018-08-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ed12e050b3, moduleTitle=Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34ed12e050b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679442, encodeId=22ff16e944202, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, objectType=article, longId=125177, objectId=1e501251e7c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e501251e7c5, replyNumber=0, likeNumber=70, createdTime=2018-08-08, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e501251e7c5, moduleTitle=EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e501251e7c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679444, encodeId=339a16e94443d, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行, objectType=article, longId=127049, objectId=a3f612e04938, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3f612e04938, replyNumber=0, likeNumber=63, createdTime=2018-03-28, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3f612e04938, moduleTitle=Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3f612e04938)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679435, encodeId=6d0116e943521, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, objectType=article, longId=108199, objectId=19871081992f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19871081992f, replyNumber=0, likeNumber=60, createdTime=2017-11-30, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19871081992f, moduleTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19871081992f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679441, encodeId=59e716e944198, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=EUR J Cancer：转移性结直肠癌患者经化疗联合西妥昔单抗或贝伐单抗治疗后的手术可行性评估：FIRE-3临床试验评估, objectType=article, longId=124475, objectId=6f811244e58b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f811244e58b, replyNumber=0, likeNumber=82, createdTime=2018-07-22, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f811244e58b, moduleTitle=EUR J Cancer：转移性结直肠癌患者经化疗联合西妥昔单抗或贝伐单抗治疗后的手术可行性评估：FIRE-3临床试验评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f811244e58b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1679436, encodeId=af2c16e94368b, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, objectTitle=CLIN CANCER RES：SMAD4缺失与头颈部肿瘤细胞西妥昔单抗耐药和MAPK/JNK活化有关, objectType=article, longId=112664, objectId=706c1126641b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=706c1126641b, replyNumber=0, likeNumber=53, createdTime=2018-05-17, rootId=0, userName=chengjn, userId=271a27776763, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=706c1126641b, moduleTitle=CLIN CANCER RES：SMAD4缺失与头颈部肿瘤细胞西妥昔单抗耐药和MAPK/JNK活化有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=706c1126641b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

西妥昔

2020-05-29

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益

2019-07-28

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌

2019-09-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

NEJM：Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌

2020-05-27

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2020-07-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

J Clin Oncol：RAS野生型转移性结直肠癌：西妥昔单抗联合FOLFOX-4 vs FOLFOX-4

2018-11-26

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA ONCOL：转移性结直肠癌首次进展后：贝伐单抗vs西妥昔单抗+化疗

2019-05-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：奥拉帕尼联合西妥昔单抗及放疗治疗局部晚期头颈部肿瘤

2019-08-12

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：miR-31-3p表达可以预测西妥昔单抗疗效

2019-11-27

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：抑制EphB4-ephrin-B信号可以增强头颈部肿瘤对西妥昔单抗-放疗的治疗反应

2019-01-24

医者仁心 (审核中...)

前往app查看评论内容

#西妥昔#

Lancet：西妥昔单抗vs顺铂治疗HPV阳性口咽鳞状细胞癌

2019-01-24

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

郭晔教授：CHANGE-2研究显示——西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益

2019-02-17

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I

2018-10-24

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Lancet：西妥昔单抗vs顺铂用于HPV阳性口腔癌

2019-05-11

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Ann Oncol：可切除的食管癌：放化疗和手术联合或不联合西妥昔单抗有差吗？

2018-08-16

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行

2018-08-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

EUR J Cancer：转移性结直肠癌治疗中，BRAF和RAS突变对一线疗法（FOLFIRI加西妥昔单抗，FOLFIRI加贝伐单抗）的影响

2018-08-08

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

Ann Oncol：顺铂+西妥昔单抗+再放疗对于复发性或第二原发性头颈部鳞状细胞癌患者可行

2018-03-28

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗

2017-11-30

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

EUR J Cancer：转移性结直肠癌患者经化疗联合西妥昔单抗或贝伐单抗治疗后的手术可行性评估：FIRE-3临床试验评估

2018-07-22

chengjn (审核中...)

前往app查看评论内容

#西妥昔#

CLIN CANCER RES：SMAD4缺失与头颈部肿瘤细胞西妥昔单抗耐药和MAPK/JNK活化有关

2018-05-17

科室
- - 订阅+
  - 更多科室
工具
服务